Physician profile
Lee S Carson
NPI 1649248576
$126,609.72
in general payments reported to CMS, 2019-2025
41 companies · $52.22 in 2025
The $52.22 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57K · 2020: $12K · 2021: $19K · 2022: $27K · 2023: $12K · 2024: $31.45 · 2025: $52.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,975 · Food and Beverage: $4,440 · Consulting Fee: $450 · Travel and Lodging: $270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,975.00 |
| Food and Beverage | $4,440.45 |
| Consulting Fee | $450.00 |
| Travel and Lodging | $269.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $56,641.46 | 2019-2023 | Rinvoq, Skyrizi |
| Regeneron Healthcare Solutions, INC. | $23,328.59 | 2019-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $14,130.40 | 2019-2023 | |
| Pfizer INC. | $10,208.30 | 2019-2023 | |
| Genzyme Corporation | $4,466.25 | 2019-2025 | |
| Promius Pharma LLC | $2,905.27 | 2019 | |
| Sun Pharmaceutical Industries INC. | $2,526.55 | 2019-2023 | Ilumya |
| Almirall LLC | $1,898.29 | 2019-2023 | Seysara |
| Mayne Pharma Commercial LLC | $1,457.18 | 2019-2023 | |
| Vyne Pharmaceuticals INC. | $1,325.26 | 2020-2021 | |
| Janssen Biotech, INC. | $1,217.92 | 2019-2023 | Tremfya, Remicade, Simponi Aria |
| Amgen INC. | $1,033.30 | 2019-2023 | Otezla |
| Ucb, INC. | $732.86 | 2019-2023 | Cimzia, Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $596.65 | 2019-2023 | Arazlo, Jublia, Siliq |
| Merz North America, INC. | $501.48 | 2019-2023 | Xeomin |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lee Carson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.